Compound formulations of 2-amino-1,3-propanediol compounds

Details for Australian Patent Application No. 2005266449 (hide)

Owner Novartis AG

Inventors Dannenfelser, Rose-Marie; Li, Ping; Buranachokpaisan, Thitiwan

Agent Davies Collison Cave

Pub. Number AU-B-2005266449

PCT Pub. Number WO2006/010630

Priority 60/592,991 30.07.04 US

Filing date 29 July 2005

Wipo publication date 2 February 2006

Acceptance publication date 8 October 2009

International Classifications

A61K 31/133 (2006.01) - having hydroxy groups, e.g. sphingosine

A61K 47/10 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Alcohols

A61P 37/00 (2006.01) Drugs for immunological or allergic disorders

A61P 37/06 (2006.01) Drugs for immunological or allergic disorders

Event Publications

8 February 2007 PCT application entered the National Phase

  PCT publication WO2006/010630 Priority application(s): WO2006/010630

8 October 2009 Application Accepted

  Published as AU-B-2005266449

4 February 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005266459-Pharmaceutical multilayer tablet for controlled release of active ingredients with highly pH-dependent solubility

2005266448-Piperazine derivatives useful for the treatment of gastrointestinal disorders